Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
Arcutis (Nasdaq: ARQT) said its management team will present at the 25th Annual Needham Virtual Healthcare Conference, April 13-16, 2026.
Rhea-AI Summary
Arcutis (Nasdaq: ARQT) said its management team will present at the 25th Annual Needham Virtual Healthcare Conference, April 13-16, 2026. The company will host a Fireside Chat on April 14, 2026 at 11:00 AM ET.
According to the company, the live webcast is available in the Events section of its website, and a replay will be accessible for 180 days after the conference.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ARQT
In the Apr 1 session, ARQT gained 2.29%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference edition
- 25th Annual
- Needham Virtual Healthcare Conference
- Conference dates
- April 13–16, 2026
- Needham Virtual Healthcare Conference schedule
- Fireside chat time
- April 14, 2026 at 11:00 am ET
- Arcutis management presentation slot
- Webcast replay duration
- 180 days
- Replay available on Arcutis website
Historical Context
-
New clinical and long-term ZORYVE data at dermatology conference.
-
Positive long-term safety and efficacy data for ZORYVE cream in children.
-
Promotion of Chief Legal Officer to support commercialization and pipeline.
-
Initiation of Phase 1a/1b study of ARQ-234 in atopic dermatitis.
-
Management participation and fireside chat at TD Cowen conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WESTLAKE VILLAGE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026.
Details for the Company’s participation are as follows:
Fireside Chat: Tuesday, April 14, 2026 at 11:00 am ET
The webcast for this conference may be accessed via the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform, coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on The Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.